Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YZJ-5053 in Advanced Solid Tumors
NCT06209385Phase 1Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YZJ-5053 in solid tumor, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
YZJ-5053
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06209385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209385.